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Introduction: Spasm of the human internal mammary artery (HIMA) 
is a rare but life-threatening complication after coronary artery 
bypass grafting (CABG). The reversal of this vasospasm is often chal-
lenging, and the most effective therapy is not well defined. The pre-
sent study was aimed to investigate vasorelaxant effect of nicorandil, 
K+ channel opener, on the HIMA and to define the role of different 
K+ channel subtypes in nicorandil action on this blood vessel.
Patients (or Materials) and Methods: Discarded segments of HIMA 
were collected from patients undergoing CABG and studied in organ 
baths. HIMA rings were precontracted with phenylephrine (10 µM) 
followed by cumulatively adding increasing doses of nicorandil. The 
endothelium was removed mechanically.
Results: Nicorandil (0.001 µM–300 µM) induced a concentration-
dependent relaxation of HIMA rings precontracted by phenylephrine. 
Glibenclamide (10 μ M), a highly selective blocker of ATP-sensitive 
K+ (KATP) channels, partially inhibited relaxation of HIMA induced 
by nicorandil. Tetraethylammonium (TEA, 1 mM), a nonselective 
blocker of Ca2+-activated K+ (KCa) channels, as well as iberiotoxin 
(100 nM), a most selective blocker of large-conductance KCa (BKCa) 
channels, partly antagonized relaxation of HIMA. A nonselective 
blocker of voltage-gated K+ (KV) channels, 4-aminopyridine (4-AP, 
0.5 mM), as well as margatoxin (10 nM), a potent inhibitor of KV1.3 
channels, did not significantly modify the nicorandil-induced relaxa-
tion of HIMA.
Conclusion: The results from our study demonstrate that, in HIMA, 
nicorandil has a potent vasorelaxant effect which is endothelium-
independent. It seems that mechanism of this relaxation includes 
KATP and 4-AP-sensitive K+ channels located in the smooth muscle 
of HIMA.
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Introduction: Thrombosis is 1 of the major causes of death world-
wide. Atherothrombotic diseases such as myocardial or cerebral 
infarction are serious consequences of the thrombus formed in 
blood vessels. Nattokinase is new fibrinolytic enzyme with a 
molecular weight of 27 728 Da that cleaves directly cross-linked 
fibrin in vitro. In this study, we investigated the effect of nat-
tokinase supplementation on thrombus formation using different 
animal models.
Patients (or Materials) and Methods: To study the fibrinolytic activ-
ity, in vitro clot dissolution assay was done in which clot was formed 
in helix and then kept in contact with different concentrations of 
nattokinase and streptokinase (standard drug) and its clot dissolution 
property was studied. Further it was studied for its antithrombotic 
activity in venous thrombosis. Rats were pretreated orally for 7 days 
with Nattokinase (100 and 200 mg/kg). One hour after the last dose, 
stasis was developed in the inferior vena cava in rats, and its activity 
was intensified with the help of ferric chloride. It was also studied 
for its antithrombotic activity in arterial thrombosis using arterio-
venous shunt-induced thrombosis in rats. In this rats were pretreated 
orally for 7 days with Nattokinase (100 and 200 mg/kg) and on last 
day 1 hour after last dose thrombosis was induced by arterio-venous 
shunt. In both the above studies, % inhibition of thrombus forma-
tion was calculated. Because hemorrhage is an important side effect 
of antithrombotic and thrombolytic therapies, the drug was studied 
for its effect on hemorrhage using rat tail transaction method. Here, 
effect of 7 days pretreatment of 2 doses of nattokinase (100 and 200 
mg/kg) on hemorrhage was studied.
Results: In in vitro clot dissolution assay, there was significant and 
dose-dependent clot dissolution with different concentration of nat-
tokinase. Maximum activity, 94.43 % inhibition, was seen in 3000ug/
mL concentration which was comparable with 1000 IU of strepto-
kinase. In venous thrombosis model, it showed significant and dose-
dependent inhibition of thrombus formation as indicated by decrease 
in weight of thrombus. Antithrombotic potential of nattokinase at the 
highest dose (200 mg/kg) showed 45.431% inhibition with respect to 
saline control group. In arterio-venous shunt ,it showed no significant 
inhibition of thrombus formation on thrombogenic surface. In the 
rat tail transaction model, both the doses of nattokinase (100 and 
200 mg/kg) has significantly increased the bleeding time with not 
much effect on blood loss. Also, the platelet MDA was significantly 
decreased in both groups treated with 100 and 200 mg/kg of nat-
tokinase.
Conclusion: The results of various in vitro and in vivo models stud-
ied indicate that nattokinase has a good potential as an antithrom-
botic and fibrinolytic agent.
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Introduction: High blood pressure (HBP) is a disease with high 
morbidity and mortality worldwide and is considered 1 of the main 
etiologic factors of multiple cardiac pathologies like cardiac hyper-
trophy, myocardial infarction, among others. One of the regulatory 
mechanisms of blood pressure is the renin angiotensin system (RAS), 
so much so that the first-line drugs in the treatment of hyperten-
sion are directed to some of the components of the RAS. However, 
these treatments frequently lead to the development of changes in 
morphology and physiology characterized by vascular complications 
.It is therefore necessary to consider adjuvant therapies to improve 
the outlook and quality of life of patients with HBP. A therapy that 
has been shown clinically to improve the condition of patients with 
HBP is hyperbaric oxygenation (HBO), which consists in subject-
ing a subject at a pressure > 2 atmospheres absolute with an 100% 
oxygen. This therapy has been shown to improve vascular smooth 
muscle relaxation, although the mechanism of action has not yet 
been specified.
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Patients (or Materials) and Methods: Male Wistar rats were used 
(340 ± 20 g) at standard conditions. Hypertension was induced by 
a previously described surgical method (PAGE), which was obtained 
with measurements HAS stable (plethysmographic method) from 
the seventh postoperative day, the eighth day began therapy OHB, 
for 5 days per week for 4 weeks. At the end of treatment, the 
rats were sacrificed getting heart; this was mounted on a system 
of isolated organ (Langendorff system), and it was stimulating to 
logarithmic doses of angiotensin II (Ang II) to measure variations in 
vascular reactivity associated with the RAS in coronary resistance 
arteries. The results are analized with 2 way ANOVA and post hoc 
Von Ferroni.
Results: The diastolic pressure measurement was obtained a pressure 
of 150 ± 15 mm Hg, consistent with the definition of hypertension. 
When analyzing perfusion pressure resistance in coronary arteries, 
the HBP group without treatment showed an increase in vascular 
reactivity compared with the healthy group. Whereas the HBP with 
HBO group no presented changes in vascular reactivity to any dose 
of Ang II, compared with healthy control group.
Conclusion: HBO therapy reduces vascular reactivity in coronary 
resistance arteries under Ang II stimulation in a model of hyperten-
sion of renal origin. This suggests that HBO could be used with 
hypertensive patients to reduce the development of heart disease and 
in another way it could help to improve the functionality of the heart 
and reduce the use of drugs in the HBP treatment.
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Introduction: Augmented pervasiveness of type 2 diabetes mellitus 
and obesity has amplified the medical necessitate for new agents to 
treat these disease states. Both type 2 diabetes and obesity are con-
nected to the resistance to the hormones insulin and leptin. Protein 
tyrosine phosphatase 1B (PTP1B) has been shown to function as 
negative regulator of insulin signaling as well as leptin signal trans-
duction. This research exertion shows the molecular docking analysis 
of novel synthetically prepared compounds and new-fangled isolated 
natural PTP 1B inhibitors as novel target for type 2 diabetes.
Patients (or Materials) and Methods: Molegro Virtual Docker 
(MVD) has been used to dock novel natural PTP1B inhibitors with 
the Discovery Studio 3.0 visualizer.
Results: Molecular docking of novel natural PTP1B inhibitors 
showed some compounds with excellent dock score with greater 
binding affinity exhibiting pi-pi interactions
Conclusion: The plausible mechanism of action of various natural 
PTP1B inhibitors has been explained supported by in vitro experi-
mentation data. Traditional drugs with unknown mechanism of 
action were experimented for the PTP1B inhibitory activity and 
therefore are attention-grabbing biologically lead compounds.
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Introduction: Cardiac arrhythmia is 1 of the critical health condi-
tions. Clofibrate is a peroxisome proliferated-activator receptor-α 
(PPAR-α ) agonist that is widely used for reducing triglycerides in 
hyperlipidemic patients. Because this drug has showed several ben-
eficial effects in relief of some cardiovascular diseases, the aim of the 
present study was to evaluate antiarrhythmic effects of clofibrate on 
ouabain-induced arrhythmia in rats.
Patients (or Materials) and Methods: Twenty male rats weighing 
220 to 250 g were divided into 2 equal groups randomly. Group 1 
(treatment) received clofibrate (300 mg/kg) solved in olive oil (1 mL/
kg) once daily for 14 days intraperitoneally. Group 2 (vehicle control) 
only received olive oil (1 mL/kg) once daily for 14 days intraperito-
neally. After induction of anesthesia, heart was rapidly removed and 
the atria were immersed in a tissue bath containing modified Krebs 
solution andattached to isometric force transducer of PowerLab 
machine. Time of onset of arrhythmia and asystole, atrial beating 
rate, and contractile force were recorded and analyzed statistically 
with paired and Student’s t test in treatment and control groups.
Results: Clofibrate significantly postponed time of onset of arrhyth-
mia (23.57 [4.69] minutes) rather than control group (2.04 [0.27] 
minutes; P = 0.024). A significant increase in the onset time of asys-
tole in treatment group (66.19 [12.33] minutes) was observed, while 
this time for control group was 22.77 (7.17) (P = 0.004). Incubation 
of ouabain increased the atrial beating rate in control group signifi-
cantly (P = 0.022), while it does not show such effect in treatment 
group (P = 0.845). Incubation of ouabain had no effects on con-
tractile force in control and treatment groups (P = 0.063 and P = 
0.539, respectively).
Conclusion: Based on the findings, clofibrate may possess poten-
tials to reduce some kinds of cardiac arrhythmias. Further studies 
especially on in vivo arrhythmial models can more elucidate these 
beneficial effects of this drug.
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Introduction: The aim of this study was to investigate whether acti-
vation of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) 
contributes to the development of endothelin-1 (ET-1)-induced 
endothelial dysfunction.
Patients (or Materials) and Methods: To evaluate vascular reactivity, 
isometric tension studies were performed in response to vasodilator 
agents, acetylcholine (ACh) and sodium nitroprusside (SNP), and con-
strictor agents, potassium chloride (KCl) and phenylephrine (Phe), 
in rat thoracic aorta rings incubated with or without ET-1(10-3 M, 
18 hours). To investigate mechanisms of ET-1 action, additional sets 
of experiments involving rings incubation with ET-1 alone or with 
addition of polyethylene glycol–superoxide dismutase (PEG-SOD, a 
cell permeable superoxide radical scavenger, 41 U/mL) plus apocynin 
(a NADPH oxidase inhibitor, 300 µM), and PJ34 (an inhibitor of 
polyADP-ribose polymerase, 3 × 10-6 M) for 18 hours, and both 
relaxant and constrictor responses were evaluated. Moreover, PARP-1 
and poly(ADP-ribose) (PAR, an end-product of PARP activity) expres-
sions were evaluated by Western blot and immunohistochemistry.
Results: The results of this study demonstrated that incubation of 
thoracic artery rings with ET-1 (10-3 M, 18 hours) resulted in sig-
nificant inhibition of response to ACh (an endothelium-dependent 
vasodilator) while SNP (an endothelium-independent vasodilator)-
